Pramipexole in the treatment of advanced Parkinson’s disease
作者： J. C. Möller , W. H. Oertel
DOI: 10.1046/J.1468-1331.2000.0070S1021.X
关键词:
摘要: Pramipexole is a novel nonergoline dopamine agonist with preference for the D3 receptor subtype. Its efficacy and safety in treatment of advanced Parkinson’s disease has been investigated several clinical studies. This review provides summary data currently available, particularly reference to recent results European phase III study potential tremorlytic activity pramipexole. Interim analysis open-label provided evidence long-term In another pramipexole shown be significantly superior placebo an improvement tremor score by 48% (vs. 13% group). addition its likely usefulness rest disease, suggest that interest due reported low frequency cardiovascular gastrointestinal side-effects. However, studies comparing other antiparkinsonian agents would useful further define benefits tremor-dominant document favourable adverse event profile.
sci-hub.se 参考文章(9)
Thomas J. Hoerger, Mohan V. Bala, Clayton Rowland, Marianne Greer, Elizabeth A. Chrischilles, Robert G. Holloway, Cost effectiveness of pramipexole in Parkinson's disease in the US. PharmacoEconomics. ,vol. 14, pp. 541- 557 ,(1998) , 10.2165/00019053-199814050-00006
Zen Faulkes, Dorothy H. Paul, A map of distal leg motor neurons in the thoracic ganglia of four decapod crustacean species. Brain Behavior and Evolution. ,vol. 49, pp. 162- 178 ,(1997) , 10.1159/000112990
Mukta Dooley, Anthony Markham, Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs & Aging. ,vol. 12, pp. 495- 514 ,(1998) , 10.2165/00002512-199812060-00007
M. Guttman, , Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease Neurology. ,vol. 49, pp. 1060- 1065 ,(1997) , 10.1212/WNL.49.4.1060
L. Wermuth, , A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. European Journal of Neurology. ,vol. 5, pp. 235- 242 ,(1998) , 10.1046/J.1468-1331.1998.530235.X
A. Lieberman, A. Ranhosky, D. Korts, Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study Neurology. ,vol. 49, pp. 162- 168 ,(1997) , 10.1212/WNL.49.1.162
M M Pinter, O Pogarell, W H Oertel, Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 66, pp. 436- 441 ,(1999) , 10.1136/JNNP.66.4.436
Oliver Pogarell, Gabriela Künig, Wolfgang H. Oertel, A non-ergot dopamine agonist, pramipexole, in the therapy of advanced Parkinson's disease : Improvement of Parkinsonian symptoms and treatment-associated complications. A review of three studies Clinical Neuropharmacology. ,vol. 20, ,(1997) , 10.1097/00002826-199720001-00005
O Pogarell, W H Oertel, J C Möller, M Delf, G Künig, Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clinical Neuropharmacology. ,vol. 22, pp. 301- 305 ,(1999)